Licensing and Technology Transfer INTELLECTUAL PROPERTY
In-licensing and out-licensing of complex, interrelated and cross-disciplinary technologies are increasingly important elements of our clients’ business strategies. Leveraging technical knowledge, business acumen and legal experience, we structure, prepare and negotiate thousands of licenses and other technology transactions each year, from the perspectives of both the licensor and the licensee. We advise clients on the licensing of technical know-how, trade secrets, patents, trademarks, copyrights and most other forms of intellectual property—relating to computer software, biotechnology and pharmaceuticals, manufacturing designs, digital content and many other technologies. We also have extensive domestic and international experience with software shrink-wrap and click-through agreements, and with strategic collaborations, research transactions and other technology transfers.

Experience

In this area, we have:

  • Assisted Nano-C Corporation in licensing projects involving domestic and foreign companies using fullerene combustion technology
  • Represented Eyetech Pharmaceuticals in its $750 million collaboration and license agreements with Pfizer to develop and commercialize ophthalmic products for the treatment of blindness—a strategic alliance selected by Recombinant Capital for its Breakthrough Alliance Award
  • Identified significant potential licensees and negotiated commercial agreements on behalf of a client with a large patent portfolio in the field of camera image presentation and processing

Publications & News

View

January 5, 2016

WilmerHale Named a Finalist in The American Lawyer's 2016 IP Litigation Department of the Year Contest

The American Lawyer has named WilmerHale as one of three finalists for 2016 Litigation Department of the Year in the Intellectual Property category. In its profile of the firm, The American Lawyer highlights WilmerHale's client commitment and its long-term strategic thinking, versatility and depth of first-chair trial talent.

December 11, 2015

Neon Therapeutics Enters License Agreement with Broad Institute, Dana-Farber and Mass General

On December 9, 2015, Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, announced that the company has entered into a license agreement with the Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital.

November 2, 2015

WilmerHale Receives Top Rankings, Named “Law Firm of the Year” in Mutual Funds Law in 2016 U.S. News - Best Lawyers® “Best Law Firms” List

U.S. News - Best Lawyers® has named WilmerHale "Law Firm of the Year" in Mutual Funds Law and recognizes the firm as a first-tier law firm in 21 national and 58 metro-area rankings. In addition, the firm boasts more than 30 second- and third-tier rankings.

July 1, 2015

WilmerHale Named a Leading National Firm in the United States by The Legal 500

The Legal 500 United States has released its annual rankings, selecting WilmerHale as one of the preeminent law firms in the country.

January 3, 2014

Three WilmerHale Practices Named ‘Practice Group of the Year’ by Law360

On January 1, 2014, WilmerHale's Appellate, Intellectual Property and Life Sciences Practices were included in Law360's "Practice Group of the Year" series for 2013.

December 6, 2013

House Passes Patent Litigation Bill

On December 5, 2013, the House of Representatives passed the Innovation Act (H.R. 3309) (the “Act”) by a vote of 325-91. The Act proposes several changes to the patent litigation system such as enhanced pleading requirements, fee shifting, discovery limits, patent ownership disclosures, and stays of customer suits.

November 1, 2013

WilmerHale Among U.S. News – Best Lawyers® “Best Law Firms” and Again Named International Arbitration “Law Firm of the Year”

The 2014 edition of the U.S. News – Best Lawyers® “Best Law Firms” list names WilmerHale as “Law Firm of the Year” in International Arbitration—this is the second consecutive year that the firm has won this honor—and honors WilmerHale as a first-tier law firm in 27 national and 60 metro-area rankings.

June 13, 2013

Supreme Court Holds Myriad’s "Naturally Occurring" DNA Claims Not Patentable

In a unanimous decision with potentially widespread ramifications, the US Supreme Court held today that “[a] naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but cDNA is patent eligible because it is not naturally occurring.”

May 13, 2013

A Divided Federal Circuit Affirms CLS Bank, Finding No Patent-Eligible Subject Matter Under 35 U.S.C. § 101

August 31, 2012

The 2013 Best Lawyers in America® List Includes 101 WilmerHale Lawyers